Clinical Trials · NCT00658697

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

Name: Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Gonadorelin

Phase: Phase 2
Recruitment status: Completed
Sponsor: Dana-Farber Cancer Institute
Enrollment: 42
Start date: Jun 2008
Locations: 3 sites, United States
Primary endpoint: Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT)

View Gonadorelin compound reference